The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2015 | Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma
Jesús San Miguel
• 12 Jun 2015
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of a phase 2 trial of monotherapy with the anti-CD38 monoclonal antibody, daratumumab, in patients with multiple myeloma who have received at least three different lines of therapy or who are double refractory.
